U.S. flag

An official website of the United States government

NM_000546.6(TP53):c.31G>A (p.Glu11Lys) AND Li-Fraumeni syndrome

Germline classification:
Conflicting interpretations of pathogenicity (2 submissions)
Last evaluated:
Dec 13, 2023
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000548671.18

Allele description [Variation Report for NM_000546.6(TP53):c.31G>A (p.Glu11Lys)]

NM_000546.6(TP53):c.31G>A (p.Glu11Lys)

Gene:
TP53:tumor protein p53 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000546.6(TP53):c.31G>A (p.Glu11Lys)
HGVS:
  • NC_000017.11:g.7676564C>T
  • NG_017013.2:g.15987G>A
  • NM_000546.6:c.31G>AMANE SELECT
  • NM_001126112.3:c.31G>A
  • NM_001126113.3:c.31G>A
  • NM_001126114.3:c.31G>A
  • NM_001126118.2:c.-204G>A
  • NM_001276695.3:c.-87G>A
  • NM_001276696.3:c.-87G>A
  • NM_001276760.3:c.-87G>A
  • NM_001276761.3:c.-87G>A
  • NP_000537.3:p.Glu11Lys
  • NP_000537.3:p.Glu11Lys
  • NP_001119584.1:p.Glu11Lys
  • NP_001119585.1:p.Glu11Lys
  • NP_001119586.1:p.Glu11Lys
  • LRG_321t1:c.31G>A
  • LRG_321:g.15987G>A
  • LRG_321p1:p.Glu11Lys
  • NC_000017.10:g.7579882C>T
  • NM_000546.4:c.31G>A
  • NM_000546.5:c.31G>A
Protein change:
E11K
Links:
dbSNP: rs201382018
NCBI 1000 Genomes Browser:
rs201382018
Molecular consequence:
  • NM_001126118.2:c.-204G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276695.3:c.-87G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276696.3:c.-87G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276760.3:c.-87G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276761.3:c.-87G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_000546.6:c.31G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126112.3:c.31G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126113.3:c.31G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126114.3:c.31G>A - missense variant - [Sequence Ontology: SO:0001583]
Observations:
1

Condition(s)

Name:
Li-Fraumeni syndrome (LFS)
Synonyms:
Sarcoma family syndrome of Li and Fraumeni
Identifiers:
MONDO: MONDO:0018875; MedGen: C0085390; OMIM: PS151623

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000629802Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Dec 13, 2023)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

SCV004823863All of Us Research Program, National Institutes of Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely Benign
(Oct 30, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided108544not providedclinical testing

Citations

PubMed

A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.

Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E.

Mol Cell. 2018 Jul 5;71(1):178-190.e8. doi: 10.1016/j.molcel.2018.06.012. Erratum in: Mol Cell. 2018 Sep 6;71(5):873. doi: 10.1016/j.molcel.2018.08.013.

PubMed [citation]
PMID:
29979965

Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner.

Abramova NA, Russell J, Botchan M, Li R.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7186-91.

PubMed [citation]
PMID:
9207066
PMCID:
PMC23787
See all PubMed Citations (6)

Details of each submission

From Invitae, SCV000629802.8

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 11 of the TP53 protein (p.Glu11Lys). This variant is present in population databases (rs201382018, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 418693). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is not expected to disrupt TP53 function with a negative predictive value of 97.5%. Experimental studies have shown that this missense change does not substantially affect TP53 function (PMID: 9207066, 12826609, 30224644). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From All of Us Research Program, National Institutes of Health, SCV004823863.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown108544not providednot provided1not providednot providednot provided

Last Updated: Jul 29, 2024